BackUltragenyx Pharmaceutical Overview

Ultragenyx Pharmaceutical Other Assets

Ultragenyx Pharmaceutical's other assets is $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer trimmed avg / median

Loading

Ultragenyx Pharmaceutical Other Assets History

Loading

Ultragenyx Pharmaceutical vs. peers: Other Assets Comparison

Loading

Ultragenyx Pharmaceutical Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ultragenyx Pharmaceutical (RARE) FAQ

Ultragenyx Pharmaceutical (RARE) currently reports a other assets of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Ultragenyx Pharmaceutical's other assets history and peer comparisons.

Ultragenyx Pharmaceutical's other assets changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ultragenyx Pharmaceutical reported $0 in other assets as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other assets of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ultragenyx Pharmaceutical, and consider following RARE for alerts when major investors trade the stock.

Ultragenyx Pharmaceutical is classified in the Healthcare sector. On other assets, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RARE with unrelated industries.